148 related articles for article (PubMed ID: 38004593)
1. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
Toja-Camba FJ; García-Quintanilla L; Rodríguez-Martinez L; Tomine J; Cajade-Pascual F; Feitosa C; Zarra-Ferro I; Barreiro-De-Acosta M; González-López J; Mondelo-García C; Fernández-Ferreiro A
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004593
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
4. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
5. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
[TBL] [Abstract][Full Text] [Related]
6. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
Valdés-Delgado T; Aguado-Paredes A; Merino-Bohórquez V; Martín-Manzanares J; Alonso MM; Maldonado B; Castro L; Belvis M; Benítez B; Caunedo Á; Calleja MÁ; Argüelles-Arias F
Dig Dis Sci; 2024 Jan; 69(1):228-234. PubMed ID: 37943382
[TBL] [Abstract][Full Text] [Related]
7. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
8. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
9. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
12. Detection of infliximab, adalimumab, and anti-drug antibodies: Development and validation of new monotest, automated assays on multiparametric instrument.
Cerutti H; Tesi G; Petrini F; Bandini T; Cartocci A; Ianniello A; Bogi A; Muzzi C; Brogi A
Pract Lab Med; 2024 Mar; 39():e00374. PubMed ID: 38463198
[TBL] [Abstract][Full Text] [Related]
13. Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center.
Tighe D; Smith S; O'Connor A; Breslin N; Ryan B; McNamara D
JGH Open; 2017 Sep; 1(1):4-10. PubMed ID: 30483525
[TBL] [Abstract][Full Text] [Related]
14. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Dias CC; Magro F;
Aliment Pharmacol Ther; 2016 Oct; 44(7):684-92. PubMed ID: 27507790
[TBL] [Abstract][Full Text] [Related]
15. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
16. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
Luo YR; Chakraborty I; Lazar-Molnar E; Wu AHB; Lynch KL
Clin Chem; 2020 Oct; 66(10):1319-1328. PubMed ID: 32918468
[TBL] [Abstract][Full Text] [Related]
17. Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting.
Volkers A; Löwenberg M; Braad M; Abeling Y; Gecse K; Berkers N; Montazeri N; D'Haens G
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238198
[No Abstract] [Full Text] [Related]
18. Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges.
Cheli S; Savino D; Penagini F; Zuccotti G; Zuin G; Clementi E; Cattaneo D
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514022
[TBL] [Abstract][Full Text] [Related]
19. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.
Rocha C; Lago P; Fernandes S; Correia L; Portela F; Vieira AI; Patita M; Arroja B; Ministro P; Alves C; Dias CC; Magro F
Therap Adv Gastroenterol; 2020; 13():1756284820965790. PubMed ID: 33281935
[TBL] [Abstract][Full Text] [Related]
20. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
